AzTrials
AzTrials

Coronary Heart DiseasePhase 4HEARTPOWERNCT07110415

Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction

A Phase 4 study testing Yangxinshi tablet in people with Coronary Heart Disease and Cardiac Dysfunction, run by SPH Qingdao Growful Pharmacetical Co.,Ltd at 96 sites in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

A randomized controlled trial was conducted to evaluate the efficacy and safety of Yangxinshi tablets in improving the condition of patients with coronary heart disease complicated by cardiac dysfunction. Read more about this study

Who is it for?
Ages 40 to 80 years
Conditions the study is for
Coronary Heart Disease, Cardiac Dysfunction
What is being tested?
Yangxinshi tablet
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
2,708 participants
Where
96 sitesChina
Study dates
6 Nov 2025to 31 Dec 2030
Phase
Phase 4
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • For inpatients diagnosed with coronary heart disease (including acute coronary syndrome and chronic coronary syndrome), it is up to the doctor to decide whether to undergo revascularization and what kind of revascularization to use.
  • Patients aged between 40 and 80 years (inclusive), regardless of sex;
  • Patients with NYHA cardiac function classes II-IV;
  • Patients with NT-proBNP > 125 pg/mL (or BNP>35 pg/mL);
  • The syndrome differentiation in traditional Chinese medicine conforms to chest obstruction (qi deficiency and blood stasis syndrome)
  • Patients who voluntarily participated and signed an informed consent form.

Who cannot join

  • Patients with STEMI within 3 days;
  • Patients at extremely high risk of NSTEMI (hemodynamic instability, cardiogenic shock, new-onset heart failure or aggravated heart failure, severe ventricular arrhythmia)
  • Patients with acute myocardial infarction complicated with cardiogenic shock, mechanical complications, respiratory failure and other multiple organ failure;
  • Patients with severe liver dysfunction (transaminase levels more than three times the upper limit of normal), renal insufficiency (eGFR < 30mL/min/1.73m2), acute infectious diseases, and mental disorders;以上翻译结果来自有道神经网络翻译（YNMT）· 通用场景
  • Patients with drug-resistant hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg);
  • Pregnant or lactating women, or those planning pregnancy during the study period;
Show all 12Show fewer
  • Patients who cannot tolerate 3 months of dual antiplatelet therapy;
  • Patients with allergic reactions or abnormal drug reactions to the study drug or any of its excipients;
  • Patients who have regularly taken Yangxinshi tablets and similar traditional Chinese medicine, Chinese patent medicine or traditional Chinese medicine decoction with the same curative effectin the past month;
  • Patients who have participated in other clinical drug trials within the last three months;
  • Patients with malignant tumors and other pathological conditions with an expected survival of less than 3 years;
  • Patients whom the investigator deems unsuitable for participating in the clinical trial.

Trial locations and contacts

96 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Han ya ling contact

024-28856114

hanyaling@263.net

96 sites in 1 country

China96 sites, 96 recruiting

  • Baoding No.1 Central Hospital

    Baoding, Hebei

    Wang hui qin

    Not yet recruiting

  • Beijing Hospital of Traditional Chinese Medicine

    Beijing, Beijing Municipality

    Shang ju ju

    Not yet recruiting

  • Dongfang Hospital,Beijing University of Chinese Medicine

    Beijing, Beijing Municipality

    Zhao hai bin

    Not yet recruiting

  • Guang'anmen Hospital,China Academy of Chinese Medical Sciences

    Beijing, Beijing Municipality

    Zhang zhen peng

    Not yet recruiting

  • Jingjiang People's Hospital

    Cangzhou, Hebei

    Chen yang

    Not yet recruiting

  • Affiliated Hospital of Changchun University of Traditional Chinese Medicine

    Changchun, Jilin

    Meng xiao ping

    Not yet recruiting

  • Jilin Provincial People's Hospital

    Changchun, Jilin

    Zhang xue lian

    Not yet recruiting

  • The First Bethune Hospital of Jilin University

    Changchun, Jilin

    Tong qian

    Not yet recruiting

  • The Second Norman Bethune Hospital of Jilin University

    Changchun, Jilin

    Liu bin

    Not yet recruiting

  • Hunan Provincial TCM Hospital

    Changsha, Hunan

    Xiong xiang hui

    Not yet recruiting

  • Chengdu Wenjiang District People's Hospital

    Chengdu, Sichuan

    Hou guo qing

    Not yet recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan

    Tian wen jie

    Not yet recruiting

  • Chifeng Municipal Hospital

    Chifeng, Neimenggu

    Liu zhi hui

    Not yet recruiting

  • Army Specialty Medical Center

    Chongqing, Chongqing Municipality

    Zeng chun yu

    Not yet recruiting

  • Chongqing Emergency Medical Center

    Chongqing, Chongqing Municipality

    Xiao jun

    Not yet recruiting

  • Chongqing General Hospital

    Chongqing, Chongqing Municipality

    Ran bo li

    Not yet recruiting

  • Chongqing University Three Gorges Hospital

    Chongqing, Chongqing Municipality

    Zhang jian ming

    Not yet recruiting

  • The Southwest Hospital of Amu

    Chongqing, Chongqing Municipality

    Zhang zhi hui

    Not yet recruiting

  • The First Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning

    Not yet recruiting

  • Dandong Central Hospital

    Dandong, Liaoning

    Jiang da ming

    Not yet recruiting

  • Daqing Oilfield General Hospital

    Daqing, Heilongjiang

    Fan zhi qing

    Not yet recruiting

  • Fushun Central Hospital

    Fushun, Liaoning

    Song zhan chun

    Not yet recruiting

  • Fuxin Central Hospital

    Fuxin, Liaoning

    Ying hai rong

    Not yet recruiting

  • Guang'an People's Hospital

    Guang’an, Sichuan

    Gou cheng

    Not yet recruiting

  • The affiliated traditional Chinese medicine hospital of Guangzhou Medical University

    Guangzhou, Guangdong

    Chen quan fu

    Not yet recruiting

  • The first affiliated hospital, Sun Yat-sen University

    Guangzhou, Guangdong

    Liao xin xue

    Not yet recruiting

  • The First Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi

    Li quan zhong

    Not yet recruiting

  • The First Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou

    Li wei

    Not yet recruiting

  • The First Affiliated Hospital of Harbin Medical University

    Haerbin, Heilongjiang

    Li yue

    Not yet recruiting

  • The Second Affiliated Hospital of Harbin Medical University

    Haerbin, Heilongjiang

    Hou jing bo

    Not yet recruiting

  • Handan Central Hospital

    Handan, Hebei

    Tian hong sen

    Not yet recruiting

  • Affiliated Hangzhou First People's Hospital,School of Medicine,Westlake University

    Hangzhou, Zhejiang

    Xu yi zhou

    Not yet recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang

    Guo xiao gang

    Zhang yun

    Not yet recruiting

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang

    Wang li hong

    Not yet recruiting

  • The People's Hospital of Bozhou

    Haozhou, Anhui

    Jiang rong yan

    Not yet recruiting

  • HeGang People's Hospital

    Hegang, Heilongjiang

    Chen feng jiao

    Not yet recruiting

  • Xuyi People's Hospital

    Huai'an, Jiangsu

    Bai song

    Not yet recruiting

  • Huzhou Central Hospital

    Huzhou, Zhejiang

    Lu kong jie

    Not yet recruiting

  • The People's Hospital of Jianyang City

    Jiancheng, Sichuan

    Luo zhi

    Not yet recruiting

  • The First Hospital of Jiaxing

    Jiaxing, Zhejiang

    Tang guan min

    Not yet recruiting

  • The Second Hospital of Jiaxing

    Jiaxing, Zhejiang

    Xu jian jiang

    Not yet recruiting

  • Jilin People's Hospital

    Jilin City, Jilin

    Zhang jin zi

    Not yet recruiting

  • Qilu Hospital of Shandong University

    Jinan, Shandong

    Yang jian min

    Not yet recruiting

  • Shandong University of Traditional Chinese Medicine Affiliated Hospital

    Jinan, Shandong

    Zhang yun

    Not yet recruiting

  • The 960th Hospital of the PLA Joint Logistics Support Force

    Jinan, Shandong

    Jin qun

    Not yet recruiting

  • The Fourth People's Hospital of Jinan

    Jinan, Shandong

    Wang tao

    Not yet recruiting

  • Yunnan Provincial Hospital of Traditional Chinese Medicine

    Kunming, Yunnan

    Luo shi hua

    Not yet recruiting

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu

    Zhang zheng

    Not yet recruiting

  • The Second People's Hospital of Liaocheng

    Liaocheng, Shandong

    Zhang yun

    Not yet recruiting

  • Liuzhou People's Hospital

    Liuzhou, Guangxi

    Liu yan li

    Not yet recruiting

  • Mudanjiang Cardiovascular Disease Hospital

    Mudanjiang, Heilongjiang

    Liu kai

    Not yet recruiting

  • Nanjing Lishui People's Hospital

    Nanjing, Jiangsu

    Chen li juan

    Not yet recruiting

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu

    Li yong jun

    Not yet recruiting

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi

    Wu xiang hong

    Not yet recruiting

  • The People's Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi

    Ji qing wei

    Not yet recruiting

  • Beilun Branch of the First Affiliated Hospital of Zhejiang University School of Medicine

    Ningbo, Zhejiang

    Wu qi

    Not yet recruiting

  • Ningbo Medical Center Lihuili Hospital

    Ningbo, Zhejiang

    Chen zhi kui

    Not yet recruiting

  • The Affiliated People'sHospital of Ningbo University

    Ningbo, Zhejiang

    Bao ying chun

    Not yet recruiting

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong

    Lian zhe xun

    Not yet recruiting

  • Fudan University Minhang Hospital

    Shanghai, Shanghai Municipality

    Hu wei

    Not yet recruiting

  • Ruijin Hospital Luban Branch, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality

    Jin wei

    Hua sha

    Not yet recruiting

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality

    Jin wei

    Chen yan jia

    Not yet recruiting

  • Shanghai Tenth People's Hospital

    Shanghai, Shanghai Municipality

    Chen wen liang

    Liu ban

    Not yet recruiting

  • Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality

    Hou lei

    Not yet recruiting

  • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality

    Zhang li

    Xu xiao lei

    Not yet recruiting

  • The Second Affiliated Hospital of Shantou University Medical College

    Shantou, Guangdong

    Chen you ren

    Not yet recruiting

  • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine

    Shaoxing, Zhejiang

    Fu guo sheng

    Wang min

    Not yet recruiting

  • General Hospital of Northern Theater Command

    Shenyang, Liaoning, 110016

    Han ya ling

    Recruiting

  • The First Hospital of China Medical University

    Shenyang, Liaoning

    Sun ying xian

    Not yet recruiting

  • The Fourth Affiliated Hospital of China Medical University

    Shenyang, Liaoning

    Jin yuan zhe

    Not yet recruiting

  • The Eighth Affiliated Hospital,Sun Yat-sen University

    Shenzhen, Shenzhen

    Huang hui

    Not yet recruiting

  • Hebei General Hospital

    Shijiazhuang, Hebei

    Dang yi

    Not yet recruiting

  • Jiangsu Provincial People's Hospital Suqian Branch

    Suqian, Jiangsu

    Zhang zhi yong

    Not yet recruiting

  • Taizhou Fourth People's Hospital

    Taizhou, Jiangsu

    Chen a di

    Not yet recruiting

  • Taizhou Central Hospital

    Taizhou, Zhejiang

    Cai hai peng

    Not yet recruiting

  • Taizhou Hospital of Zhejiang Province

    Taizhou, Zhejiang

    Jiang jian jun

    Not yet recruiting

  • Tengzhou Central People's Hospital

    Tengzhou, Shandong

    Yan jing peng

    Not yet recruiting

  • The Second Hospital of Tianjin Medical University

    Tianjin, Tianjin Municipality

    Liu tong

    Not yet recruiting

  • Tianjin Chest Hospital

    Tianjin, Tianjin Municipality

    Cong hong liang

    Not yet recruiting

  • Tianjin Fifth Center Hospital

    Tianjin, Tianjin Municipality

    Wang kuan

    Not yet recruiting

  • Tianjin Hospital of Integrated Traditional Chinese and Western Medicine

    Tianjin, Tianjin Municipality

    Li yong jian

    Not yet recruiting

  • Affiliated Hospital of Shandong Second Medical University

    Weifang, Shandong

    Duan lu chang

    Not yet recruiting

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi

    Deng jie

    Not yet recruiting

  • Xi'an Gaoling District Hospital

    Xi’an, Shanxi

    Wang yan

    Not yet recruiting

  • Xingtai People's Hospital

    Xingtai, Hebei

    Zhang you liang

    Not yet recruiting

  • Xuzhou No.1 People's Hospital

    Xuzhou, Jiangsu

    Zhao yue wu

    Not yet recruiting

  • PLA Joint Logistics Support Force No.970 Hospital

    Yantai, Shandong

    Wang hai tao

    Not yet recruiting

  • Yantai Affiliated Hospital of Binzhou Medical University

    Yantai, Shandong

    Cui ai dong

    Not yet recruiting

  • Yantai Yuhuangding Hospital

    Yantai

    Ren fa xin

    Not yet recruiting

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia

    Qiu yu ming

    Not yet recruiting

  • Yiyang Central Hospital

    Yiyang, Hunan

    He hui

    Not yet recruiting

  • The First Affiliated Hospital of Hebei North University

    Zhangjiakou, Hebei

    Li fang jiang

    Not yet recruiting

  • The 7th People's Hospital of Zhengzhou

    Zhengzhou, Henan

    Yuan li xia

    Not yet recruiting

  • The Third People's Hospital of Zhengzhou

    Zhengzhou, Henan

    Bai dong yang

    Not yet recruiting

  • The Fifth Affiliated Hospital,Sun Yat-sen University

    Zhuhai, Guangdong

    Jin li zi

    Not yet recruiting

  • The First Affiliated Hospital of Zunyi Medical University"

    Zunyi, Guizhou

    Shi bei

    Not yet recruiting

Other trials in China

About this study

Official title: A Randomized Controlled Trial of the Efficacy and Safety of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction

A randomized controlled trial was conducted to evaluate the efficacy and safety of Yangxinshi tablets in improving the condition of patients with coronary heart disease complicated by cardiac dysfunction.

Read the detailed description

The purpose of this study was to investigate whether the addition of Yangxinshi tablets to conventional treatment can reduce the composite endpoint time, increase exercise tolerance, and improve quality of life and mental health in patients with coronary heart disease complicated by cardiac dysfunction. A total of 2708 eligible patients were randomly divided into two groups. In addition to conventional treatment, the trial group was given Yangxinshi tablets (3 tablets/time, 3 times/day), while the control group was a blank control. The treatment cycle continued until the expected number of endpoint events was reached or the study ended, whichever occurred first. The primary endpoint was the composite endpoint of ischemic events or heart failure-related clinical events (including all-cause death, ischemia-driven revascularization, stroke, myocardial infarction (MI), and readmission due to aggravated ACS or heart failure) during the study period.

Being tested
Yangxinshi tablet, Blank control
Keywords
Yangxinshi, Coronary heart disease, Cardiac dysfunction
Medical subject headings
Coronary Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Yangxinshi tabletDrug

    Also called Yangxinshi

    Basic treatment: All patients received a conventional treatment regimen, including outcome-improving drugs (aspirin, P2Y12 receptor inhibitor、β-blockers, statins, ARNI /ACEI/ARB, SGLT2i, and MRA) and symptom-relieving drugs (nitrates, calcium antagonists, and loop diuretic).

    Trial drug: Yangxinshi tablets, 3 tablets/3 times a day, taken orally

  • Blank controlDrug

    Basic treatment: All patients received a conventional treatment regimen, including outcome-improving drugs (aspirin, P2Y12 receptor inhibitor、β-blockers, statins, ARNI /ACEI/ARB, SGLT2i, and MRA) and symptom-relieving drugs (nitrates, calcium antagonists, and loop diuretic).

    Trial drug: Blank control

Study groups in NCT07110415
Study groupRoleWhat they receive
Trial groupExperimentalBasic treatment and Trial drug
Receives: Drug: Yangxinshi tablet
Control groupSham comparatorBasic treatment
Receives: Drug: Blank control

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The composite endpoint was ischemic events or heart failure-related clinical events

    All-cause death, ischemia-driven revascularization, stroke, MI, and readmission due to aggravated ACS or heart failure

    Measured: Through study completion, an average of 3 years

Secondary outcomes (21)

  1. Ischemic composite endpoint events

    Cardiovascular and cerebrovascular death, MI, ischemia-driven revascularization, stroke, and readmission due to ACS

    Measured: Through study completion, an average of 3 years

  2. Heart failure-related clinical events

    Readmission due to aggravated heart failure or all-cause death

    Measured: Through study completion, an average of 3 years

  3. Cardiovascular and cerebrovascular deaths

    Occurrence of cardiovascular and cerebrovascular deaths

    Measured: Through study completion, an average of 3 years

  4. All-cause death

    Occurrence of all-cause death

    Measured: Through study completion, an average of 3 years

  5. Readmission due to ACS

    Readmission due to ACS

    Measured: Through study completion, an average of 3 years

  6. Readmission due to aggravated heart failure

    Readmission due to aggravated heart failure

    Measured: Through study completion, an average of 3 years

  7. The cumulative incidence of readmission due to aggravated ACS or heart failure

    The joint gamma frailty model was adopted for analysis

    Measured: Through study completion, an average of 3 years

  8. Win ratio

    The main efficacy indicators were analyzed by using the win ratio method

    Measured: Through study completion, an average of 3 years

  9. 6MWD

    Change in 6-minute walking distance

    Measured: From baseline at 48 weeks

  10. NT-proBNP or BNP

    Measurement of NT-proBNP or BNP, calculation of the proportion of patients achieving NT-proBNP <125 pg/mL (or BNP <35 pg/mL), and the degree of reduction

    Measured: From baseline at 48 weeks

  11. Patient Health Questionnaire - 9(PHQ-9) depression scale

    The Patient Health Questionnaire - 9(PHQ-9)depression scale comprises nine questions. In each assessment area, scores range from 0 to 3 based on the increasing frequency of difficult: 0 indicates "not at all," 1 indicates "sometimes," 2 indicates "more than half the time," and 3 indicates "almost every day." The total score ranges from 0 to 27,higher scores mean a worse outcome.

    Measured: After 24 and 48 weeks of treatment

  12. Generalized Anxiety Disorder 7 - item Scale(GAD-7) anxiety scale

    The Generalized Anxiety Disorder 7 - item Scale(GAD-7) anxiety scale comprises seven questions. In each assessment area, scores range from 0 to 3 based on the increasing frequency of difficult: 0 indicates "not at all," 1 indicates "sometimes," 2 indicates "more than half the time," and 3 indicates "almost every day." The total score ranges from 0 to 21,higher scores mean a worse outcome.

    Measured: After 24 and 48 weeks of treatment

  13. NYHA

    Changes in New York Heart Association (NYHA) functional classification

    Measured: After 24 and 48 weeks of treatment

  14. SAQ

    Changes in Seattle Angina Questionnaire (SAQ) scores.The SAQ scale is divided into 5 dimensions, with a total of 19 items, and each item is scored out of 100 points. The higher the score, the better the therapeutic effect

    Measured: After 24 and 48 weeks of treatment

  15. KCCQ-OS

    Changes in Kansas City Cardiomyopathy Questionnaire overall score (KCCQ-OS) compared to baseline.The total score ranges from 0 to 100,higher scores mean a better outcome.

    Measured: After 24 and 48 weeks of treatment

  16. Echocardiography

    Changes from baseline examined via echocardiography, including left ventricular systolic function (left ventricular end-diastolic diameter (LVDd), left ventricular end-systolic diameter (LVSd), left ventricular ejection fraction (LVEF), left ventricular fractional shortening (FS) and left ventricular diastolic function (E/A and E/e) . When possible, the left ventricular global longitudinal strain rate (LVGLS) was also measured

    Measured: After 48 weeks of treatment

  17. Metabolic equivalents(METs)

    Changes in metabolic equivalents(METs) determined by cardiopulmonary exercise testing in some patients.

    Measured: After 48 weeks of treatment

  18. Anaerobic thresholds (ATs)

    Changes in anaerobic thresholds (ATs) determined by cardiopulmonary exercise testing in some patients.

    Measured: After 48 weeks of treatment

  19. Maximal oxygen consumption (VO2max)

    Changes in maximal oxygen consumption (VO2max) determined by cardiopulmonary exercise testing in some patients.

    Measured: After 48 weeks of treatment

  20. VO2/heart rate(HR)

    Changes in VO2/HR determined by cardiopulmonary exercise testing in some patients.

    Measured: After 48 weeks of treatment

  21. The ratio of the change in VO2 to the change in the work rate (△VO2/△WR)

    Changes in △VO2/△WR determined by cardiopulmonary exercise testing in some patients.

    Measured: After 48 weeks of treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Aug 2025
  2. Study start6 Nov 2025
  3. Primary completion31 Aug 2030 (estimated)
  4. Study completion31 Dec 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
2,708 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07110415
Sponsor's protocol ID
Growful2401YXS
Acronym
HEARTPOWER
Status last verified
Nov 2025
First submitted
22 Jul 2025
Last updated
25 Nov 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, Banning AP, Budaj A, Buechel RR, Chiariello GA, Chieffo A, Christodorescu RM, Deaton C, Doenst T, Jones HW, Kunadian V, Mehilli J, Milojevic M, Piek JJ, Pugliese F, Rubboli A, Semb AG, Senior R, Ten Berg JM, Van Belle E, Van Craenenbroeck EM, Vidal-Perez R, Winther S; ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024 Sep 29;45(36):3415-3537. doi: 10.1093/eurheartj/ehae177. No abstract available.

    PubMed 39210710

  • Li Y, Li Y, Zhang Z, Zhang J, Chen H, Yu H, Meng X, Yuan H, Shao L, Lu Y, Liu B, Xu J, Zhang Y, Li J, Han Y; HEARTRIP investigators. Efficacy and safety of yangxinshi versus trimetazidine on exercise tolerance in patients with coronary heart disease after percutaneous coronary intervention: Multicenter, double-blind clinical trial. Phytomedicine. 2024 Dec;135:156198. doi: 10.1016/j.phymed.2024.156198. Epub 2024 Nov 7.

    PubMed 39566404

  • Zhang S, Shen Y, Liu P, Meng X, Hu D. Yangxinshi Tablet Improves Exercise Capacity for Patients with Coronary Heart Disease: Results from a Randomized, Double-Blind, Placebo-Controlled, and Multicenter Trial. Rev Cardiovasc Med. 2022 Jul 21;23(8):266. doi: 10.31083/j.rcm2308266. eCollection 2022 Aug.

    PubMed 39076617

  • Rao SV, O'Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, Baber U, Baker H, Cohen MG, Cruz-Ruiz M, Davis LL, de Lemos JA, DeWald TA, Elgendy IY, Feldman DN, Goyal A, Isiadinso I, Menon V, Morrow DA, Mukherjee D, Platz E, Promes SB, Sandner S, Sandoval Y, Schunder R, Shah B, Stopyra JP, Talbot AW, Taub PR, Williams MS; Peer Review Committee Members. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025 Jun 10;85(22):2135-2237. doi: 10.1016/j.jacc.2024.11.009. Epub 2025 Feb 27.

    PubMed 40013746

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Yangxinshi tablet in people with Coronary Heart Disease and Cardiac Dysfunction, run by SPH Qingdao Growful Pharmacetical Co.,Ltd at 96 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 25 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 96 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Han ya ling (024-28856114, hanyaling@263.net), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The composite endpoint was ischemic events or heart failure-related clinical events (time frame: Through study completion, an average of 3 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07110415, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Nov 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in